{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:52:50Z","timestamp":1789912370239,"version":"4.0.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Institutes of Health (US)- Alliance Chairman's Grant","award":["U10CA180821"],"award-info":[{"award-number":["U10CA180821"]}]},{"name":"National Institutes of Health (US)-Alliance Statistics and Data Center Grant","award":["U10CA180882"],"award-info":[{"award-number":["U10CA180882"]}]},{"name":"National Institutes of Health (US)- Alliance NCORP Grant","award":["UG1CA189823"],"award-info":[{"award-number":["UG1CA189823"]}]},{"name":"National Institutes of Health (US) Alliance NCTN Biorepository and Biospecimen Resource Grant","award":["U24CA196171"],"award-info":[{"award-number":["U24CA196171"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s11060-019-03194-z","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:27:56Z","timestamp":1558571276000},"page":"573-581","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE\/NCCTG)"],"prefix":"10.1007","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7827-463X","authenticated-orcid":false,"given":"Kurt A.","family":"Jaeckle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. K.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin L.","family":"Twohy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse G.","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrill J.","family":"Egorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jann N.","family":"Sarkaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. J.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Schwerkoske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan C.","family":"Buckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Galanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,22]]},"reference":[{"key":"3194_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/jnen\/59.6.495","volume":"59","author":"JS Smith","year":"2000","unstructured":"Smith JS, Wang XY, Qian J, Hosek SM, Scheithauer BW, Jenkins RB, James CD (2000) Amplification of the platelet-derived growth factor receptor -A (PDGFRA) gene occurs in oligodendrogliomas with Grade IV anaplastic features. J Neuropathol Exp Neurol 59:495\u2013503","journal-title":"J Neuropathol Exp Neurol"},{"key":"3194_CR2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/00006123-199802000-00080","volume":"42","author":"F DiRocco","year":"1998","unstructured":"DiRocco F, Carroll RS, Zhang J, Black PM (1998) Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. Neurosurgery 42:341\u2013346","journal-title":"Neurosurgery"},{"key":"3194_CR3","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s11060-009-9975-4","volume":"96","author":"E Ranza","year":"2010","unstructured":"Ranza E, Mazzini G, Facoetti A, Nano R (2010) In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation. J Neurooncol 96:349\u2013357","journal-title":"J Neurooncol"},{"key":"3194_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2307\/2530297","volume":"38","author":"TR Fleming","year":"1982","unstructured":"Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38:143\u2013151","journal-title":"Biometrics"},{"key":"3194_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2307\/2531951","volume":"43","author":"D Duffy","year":"1987","unstructured":"Duffy D, Santner T (1987) Confidence intervals for a binomial parameter based on multistage tests. Biometrics 43:81\u201393","journal-title":"Biometrics"},{"key":"3194_CR6","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","volume":"26","author":"C Clopper","year":"1934","unstructured":"Clopper C, Pearson ES (1934) The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26:404\u2013413","journal-title":"Biometrika"},{"key":"3194_CR7","volume-title":"Practical statistics for medical research","author":"DG Altman","year":"1991","unstructured":"Altman DG (1991) Practical statistics for medical research. Chapman and Hall, London"},{"key":"3194_CR8","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1056\/NEJM198408163110705","volume":"311","author":"LE Moses","year":"1984","unstructured":"Moses LE, Emerson JD, Hosseini H (1984) Analyzing data from ordered categories. New Engl J Med 311:442\u2013448","journal-title":"New Engl J Med"},{"key":"3194_CR9","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S0360-3016(98)00352-6","volume":"42","author":"SV Rajkumar","year":"1998","unstructured":"Rajkumar SV, Buckner JC, Schomberg PJ, Reid JM, Bagniewski PJ, Ames MM, Cascino TL, Marks PS (1998) Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin and etoposide and accelerated radiotherapy in patients with high-grade gliomas. Int J Radiat Oncol Biol Phys 42:969\u2013975","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3194_CR10","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/ijc.27606","volume":"131","author":"I Appollini","year":"2012","unstructured":"Appollini I, Calzolari F, Barilari M, Terrile M, Daga A, Malatesta P (2012) Antagonistic modulation of gliomagenesis by Pax6 and Olig2 in PDGF-induced oligodendroglioma. Int J Cancer 131:1078\u20131087","journal-title":"Int J Cancer"},{"key":"3194_CR11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1593\/neo.04691","volume":"7","author":"C Dai","year":"2005","unstructured":"Dai C, Lyustikman Y, Shih A, Hu X, Fuller GN, Rosenblum M, Holland EC (2005) The characteristics of astrocytomas and oligodendrogliomas are caused by two distinct and interchangeable signaling formats. Neoplasia 7:397\u2013406","journal-title":"Neoplasia"},{"key":"3194_CR12","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1002\/ijc.25869","volume":"129","author":"T Doucette","year":"2011","unstructured":"Doucette T, Yang Y, Zhang W, Fuller GN, Suki D, Fults DW, Rao G (2011) Bcl-2 promotes malignant progression in a PDGF-B-dependent murine model of oligodendroglioma. Int J Cancer 129:2093\u20132103","journal-title":"Int J Cancer"},{"key":"3194_CR13","first-page":"1","volume":"25","author":"MR Hassler","year":"2014","unstructured":"Hassler MR, Vedadinejad M, Flechl B (2014) Response to imatinib as a function of target kinase expression in recurrent glioblastoma. Springerplus 25:1\u20139","journal-title":"Springerplus"},{"key":"3194_CR14","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s00776-010-1506-9","volume":"15","author":"J Sugiura","year":"2010","unstructured":"Sugiura J, Fujiwara Y, Ando M, Kawai A, Ogose A, Ozaki T, Yokoyama R, Hiruma T, Ishii T, Morioka H, Mugishima H (2010) Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma. J Orthop Sci 15:654\u2013660","journal-title":"J Orthop Sci"},{"key":"3194_CR15","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/ijc.24030","volume":"124","author":"T Shingu","year":"2009","unstructured":"Shingu T, Fujiwara K, Bogler O, Akiyama Y, Moritake K, Shinojima N, Tamada Y, Yoyoyama T, Kondo S (2009) Inhibition of autophagy at a late stage enhances imatinib-induced cytotoxicity in human malignant glioma cells. Int J Cancer 124:1060\u20131071","journal-title":"Int J Cancer"},{"key":"3194_CR16","first-page":"1972","volume":"9","author":"JR Johnson","year":"2003","unstructured":"Johnson JR, Bross P, Cohen M, Rothmann M, Chen G, Zajicek A, Gobburu J, Rahman A, Staten A, Pazdur R (2003) Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clin Cancer Res 9:1972\u20131979","journal-title":"Clin Cancer Res"},{"key":"3194_CR17","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","volume":"44","author":"B Peng","year":"2005","unstructured":"Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879\u2013894","journal-title":"Clin Pharmacokinet"},{"key":"3194_CR18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.4149\/neo_2009_03_202","volume":"5","author":"K Czyzewski","year":"2009","unstructured":"Czyzewski K, Styczynski J (2009) Imatinib is a substrate for various multidrug resistance proteins. Neoplasma 5:202\u2013207","journal-title":"Neoplasma"},{"key":"3194_CR19","doi-asserted-by":"publisher","first-page":"6258","DOI":"10.1158\/1078-0432.CCR-08-1867","volume":"15","author":"E Razis","year":"2009","unstructured":"Razis E, Selviaridis P, Labropoulos S, Norris JL, Zhu MJ, Song DD, Kalebic T, Torrens M, Kalogera-Founzila A, Karkavelas G, Karanastasi S, Fletcher JA, Fountzilas G (2009) Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of treatment. Clin Cancer Res 15:6258\u20136566","journal-title":"Clin Cancer Res"},{"key":"3194_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11060-006-9302-2","volume":"83","author":"A Desjardins","year":"2007","unstructured":"Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, McLendon RE, Provenzale JM, Rich JN, Sampson JH, Gururangan S, Dowell JM, Salvado A, Friedman HS, Reardon DA (2007) Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III gliomas. J Neurooncol 83:53\u201360","journal-title":"J Neurooncol"},{"key":"3194_CR21","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1038\/sj.bjc.6605411","volume":"101","author":"DA Reardon","year":"2009","unstructured":"Reardon DA, Dresemann G, Campone Taillibert S, M, van den Bent M, Clement P, Blomquist E, Gordower L, Schultz H, Raizer J, Hau P, Easaw J, Gil M, Tonn J, Gijtenbeek A, Schlegel U, Bergstrom P, Green S, Weir A, Nikolova Z, (2009) Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer 101:1995\u20132004","journal-title":"Br J Cancer"},{"key":"3194_CR22","doi-asserted-by":"publisher","first-page":"4899","DOI":"10.1158\/1078-0432.CCR-06-0773","volume":"12","author":"PY Wen","year":"2006","unstructured":"Wen PY, Yung WK, Norden Lamborn KR, AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD, (2006) Phase I\/II study of imatinib mesylate for recurrent malignant gliomas. North American Brain Tumor Consortium Study 99\u201308. Clin Cancer Res 12:4899\u20134907","journal-title":"Clin Cancer Res"},{"key":"3194_CR23","doi-asserted-by":"publisher","first-page":"4759","DOI":"10.1002\/cncr.26541","volume":"118","author":"DA Reardon","year":"2012","unstructured":"Reardon DA, Desjardins A, Vredenburgh JJ, Herndon JE, Coan A, Gururangan S, Peters KB, McLendon R, Sathornsumettee S, Rich JN, Lipp ES, Janney D, Friedman HS (2012) Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. Cancer 118:4759\u20134767","journal-title":"Cancer"},{"key":"3194_CR24","doi-asserted-by":"publisher","first-page":"4659","DOI":"10.1200\/JCO.2008.16.9235","volume":"26","author":"Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert G, Clement PM, Frenay M, Rampling R, Stupp R, Kros JM, Heinrich MC, Gorlia T, Lacombe D, van den Bent MJ, European Organisation for Research and Treatment of Cancer Brain Tumor Group Study","year":"2008","unstructured":"Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert G, Clement PM, Frenay M, Rampling R, Stupp R, Kros JM, Heinrich MC, Gorlia T, Lacombe D, van den Bent MJ, European Organisation for Research and Treatment of Cancer Brain Tumor Group Study (2008) Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 26:4659\u20134665","journal-title":"J Clin Oncol"},{"key":"3194_CR25","first-page":"452","volume":"50","author":"F Van Obbergh","year":"2017","unstructured":"Van Obbergh F, Knoops L, Devos T, Beguin Y, Graux C, Benghiat F, Kargar-Samani K, Bauwens D, Efira A, Dubois C, Springael C, Monfort L, Connerotte T, Capron A, Delannoy A, Wallemacq P (2017) The clinical relevance of imatinib trough concentrations in chronic myeloid leukemia. A Belgian Study. Clin Biochem 50:452\u2013454","journal-title":"A Belgian Study. Clin Biochem"},{"key":"3194_CR26","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1080\/10428190310001625728","volume":"45","author":"JF Leis","year":"2004","unstructured":"Leis JF, Stepan DE, Curtin PT, Ford JM, Peng B, Schubach S, Druker BJ, Maziarz RT (2004) Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma 45:695\u2013698","journal-title":"Leuk Lymphoma"},{"key":"3194_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2176\/nmc.22.81","volume":"22","author":"K Harada","year":"1982","unstructured":"Harada K, Kiya K, Matsumura S, Mori S, Uozumi T (1982) Spontaneous intracranial hemorrhage caused by oligodendroglioma\u2014a case report and review of the literature. Neurol Med Chir (Tokyo) 22:81\u201384","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"3194_CR28","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803\u2013820","journal-title":"Acta Neuropathol"}],"updated-by":[{"DOI":"10.1007\/s11060-019-03201-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T00:00:00Z","timestamp":1559692800000}}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-019-03194-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-019-03194-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-019-03194-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T23:14:54Z","timestamp":1590016494000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-019-03194-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,22]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["3194"],"URL":"https:\/\/doi.org\/10.1007\/s11060-019-03194-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s11060-019-03201-3","asserted-by":"object"}]},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,22]]},"assertion":[{"value":"22 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2019","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The last author's first name was truncated in the initial online publication. The original article has been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"the authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}